Limaca Medical

Company Overview

Snapshot

Founded in January 2015 by Assaf Klein and Iyad Khamaysi, Limaca Medical operates with 1–10 employees. The company has secured $1.25 million across two funding rounds from four investors, including The Trendlines Group. In November 2024, Limaca Medical's Precision-GI was granted CMS Transitional Pass-Through (TPT) Payment, signaling significant market access.

Business overview

Limaca Medical develops KORA, an electro-mechanically driven endoscopic ultrasound-guided biopsy product designed to improve the diagnosis of gastrointestinal system tumors. The core technology focuses on obtaining higher-quality core tissue for superior histopathologic analysis, leading to improved diagnostic accuracy and better clinical outcomes. Initially targeting pancreatic tumors, the company plans to expand into liver and lung cancer markets. Limaca Medical operates within the Health Tech & Life Sciences sector, specifically in medical devices, diagnostics devices, and ultrasound technologies, serving healthcare providers globally.

Strategic signal

In November 2024, Limaca Medical's Precision-GI received CMS Transitional Pass-Through (TPT) Payment. This designation is a critical market access signal for investors, indicating that the device has met specific criteria for new medical technologies that offer substantial clinical improvement, potentially accelerating its adoption and reimbursement within the US healthcare system and validating its commercial viability.

Company Intelligence Q&A

What is Limaca Medical's primary product?

Limaca Medical is developing KORA, an electro-mechanically driven endoscopic ultrasound-guided biopsy product designed for improved diagnosis of gastrointestinal system tumors, including pancreatic, liver, and lung cancer.

When did Limaca Medical receive FDA Breakthrough Device Designation for its Precision-GI product?

In May 2022, Limaca Medical received Breakthrough Device designation from the FDA for its Precision-GI product.

When did Limaca Medical raise its last disclosed funding round?

In November 2020, Limaca Medical raised $1.25 million. The round included investment from The Trendlines Group and Carl Rickenbaugh.

When did Limaca Medical announce its partnership in Japan?

In May 2022, Limaca Medical announced a partnership with HekaBio to expand its presence in Japan.

When did Limaca Medical complete its 24 EUS pancreatic and liver biopsy cases?

In May 2024, Limaca Medical completed 24 EUS pancreatic and liver biopsy cases, demonstrating progress in clinical validation of its technology.